Target intelligence / Profile preview

C-type lectin domain family 5 member A (CLEC5A)

Target
CLEC5A
Molecular classification
Receptor, C-type lectin, Type II transmembrane protein, Immune receptor
01

Overview

C-type lectin domain family 5 member A (CLEC5A) is a type II transmembrane protein belonging to the C-type lectin receptor family, expressed predominantly on myeloid cells such as neutrophils, monocytes, macrophages, osteoclasts, microglia, and dendritic cells. Structurally, CLEC5A features a lectin-like domain and requires the adaptor protein DAP12 for signal transduction through the Syk kinase pathway; this is due to its short cytoplasmic tail that lacks signaling motifs. CLEC5A is a critical macrophage receptor for several viruses (notably dengue, influenza, and Japanese encephalitis virus): viral binding triggers DAP12 phosphorylation and causes secretion of pro-inflammatory cytokines, amplifying the innate immune response and contributing to diseases such as dengue hemorrhagic fever and dengue shock syndrome. CLEC5A also positively regulates osteoclastogenesis and participates in virus-induced pathology and inflammatory diseases. CLEC5A is under active investigation as a therapeutic target by blocking its activity (e.g., monoclonal antibodies, Syk inhibitors) to attenuate inflammatory damage in viral infections.

Other names
C-type lectin domain containing 5ACLEC5ACLECSF5MDL1MDL-1C-type lectin superfamily member 5Myeloid DAP12-associating lectin 1
02

Mechanism of action

Blockade of ligand binding to CLEC5A inhibits downstream signaling and pro-inflammatory cytokine release; Syk pathway inhibition interrupts signal transduction after CLEC5A activation

03

Biological functions

Innate immune responseCell activationCytokine and chemokine releaseSignal transduction via DAP12/Syk pathwayRegulation of osteoclastogenesisVirus recognition
04

Disease associations

Infection (dengue virus, influenza, Japanese encephalitis virus)InflammationHemorrhagic fever and shock syndrome (dengue)Cancer (Penis squamous cell carcinoma)
05

Safety considerations

Inhibition may dampen innate immune responses, increasing infection riskPossible impact on bone turnover due to osteoclast regulation
06

Interacting drugs

Anti-CLEC5A monoclonal antibodies (experimental)

1 more in the full profile.

07

Biomarkers

CLEC5A expression on myeloid cells for identification and patient selection in inflammatory or viral conditionsCytokine measurement in response to CLEC5A stimulation for efficacy monitoring

Beyond the preview

Go deeper on C-type lectin domain family 5 member A (CLEC5A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-type lectin domain family 5 member A (CLEC5A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call